MethylGene Announces the Appointment of Dr. Charles M. Baum

MethylGene Announces the Appointment of Dr. Charles M. Baum as
President and CEO and Changes to the Board of Directors 
MONTREAL, QUEBEC -- (Marketwire) -- 11/12/12 -- MethylGene Inc.
("MethylGene" or the "Company") (TSX:MYG) today announced that
Charles M. Baum, MD, PhD, has been appointed to the position of
President and Chief Executive Officer and has joined the Company's
Board of Directors, effective immediately. MethylGene also announced
that Mr. Louis Lacasse and Mr. Colin Mallet have stepped down from
the Board of Directors. 
Dr. Baum was most recently Senior Vice President for Clinical
Research within Pfizer's Worldwide Research & Development division.
He has worked at Pfizer since 2003, taking on roles of increasing
responsibility, including Vice President and Head of Oncology
Development and Chief Medical Officer for Pfizer's Biotherapeutics
and Bioinnovation Center, a Pfizer division comprised of small
biotech research units. During his tenure at Pfizer he was
responsible for the development of the oncology portfolio, including
the tyrosine kinase inhibitors sunitinib (Sutent(R)), axitinib
(Inlyta(R)) and crizotinib (Xalkori(R)). Prior to joining Pfizer Dr.
Baum was responsible for the Phase I-IV development of several
oncology compounds at Schering-Plough, including temozolomide
(Temodar(R)). His career also includes academic and hospital
positions at Stanford and Emory Universities, as well as positions of
increasing responsibility within the pharmaceutical industry
(Systemix, Searle, Schering-Plough and Pfizer).  
"I am delighted to welcome Dr. Baum to lead the Company at this
important point in our development" said Dr. Martin Godbout, Chairman
of the Board of Directors. "His exceptional experience in drug
development will be of tremendous value to the advancement of our
oncology and antifungal programs. I would also like to extend my most
sincere thanks to Mr. Louis Lacasse and Mr. Colin Mallet for their
longstanding and dedicated support as members of our Board of
Directors." 
"I am very excited to join MethylGene," said Dr. Baum. "MGCD265 and
MGCD290 are based upon impressive science and encouraging early phase
clinical data. The MethylGene team has established a strong
foundation for expanded clinical development. We will continue to
focus our eff
orts on realizing the potential of these novel therapies
to address the unmet needs of patients with cancer and fungal
infections." 
Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from the
Washington University School of Medicine and did his post-graduate
work at Stanford University, where he completed his medical training
and conducted research on human bone marrow stem cells with Dr.
Irving Weissman. Dr. Baum was granted research support by the
National Institutes of Health and the American Cancer Society,
published more than 50 peer-reviewed manuscripts, and holds a number
of patents and patent applications. 
About MethylGene 
MethylGene Inc. (TSX:MYG) is a drug development company that is
advancing novel therapeutics for cancer and infectious disease in
human clinical trials. The Company's lead product candidates are:
MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme
that is in a Phase II trial for vulvovaginal candidiasis, and
MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase
I/II clinical trials for patients with solid tumors. MethylGene owns
all rights to its lead product candidates, and has partnerships with
Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and
EnVivo Pharmaceuticals, Inc. for its other pipeline programs. 
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date
hereof, may constitute forward-looking statements. Such statements,
based as they are on the current expectations of management of
MethylGene, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond MethylGene's control.
These risks and uncertainties could cause future results, performance
or achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Such results, performance or achievements include, but
are not limited to, the timing and effects of regulatory action; the
continuation of collaborations; the results of clinical trials; the
timing of enrollment or completion of clinical trials; the success,
efficacy or safety of MGCD265, MGCD290 or our other programs; the
ability to scale up, formulate and manufacture sufficient GMP,
clinical or commercialization quantities of MGCD265, MGCD290 or our
other products, and the relative success or the lack of success in
developing and gaining regulatory approval and/or market acceptance
for any compound or new product including MGCD265 or MGCD290. Such
risks include, but are not limited to, the impact of general economic
conditions, economic conditions in the pharmaceutical industry,
changes in the regulatory environment in the jurisdictions in which
MethylGene does business, stock market volatility, fluctuations in
costs, expectations with respect to our intellectual property
position and our ability to protect our intellectual property and
operate our business without infringing upon the intellectual
property rights of others, changes in the competitive landscape
including changes in the standard of care for the various indications
in which MethylGene is involved, and changes to the competitive
environment due to consolidation, as well as other risks, as
described in MethylGene's Annual Information Form under the heading
"Risk Factors" which you are urged to read, and all other documents
filed by the Company that can be found at www.sedar.com.
Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The
reader should not place undue reliance on the forward-looking
statements included in this news release. These statements speak only
as of the date they are made and MethylGene expressly disclaims any
duty, obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in MethylGene's expectations with regard thereto
of any change in events, conditions or circumstances on which any
such statements are based except in accordance with law.
Contacts:
MethylGene Inc.
Joseph Walewicz, CFA
Vice President, Business & Corporate Development
514-337-3333 ext. 373
ir@methylgene.com
www.methylgene.com 
The Trout Group LLC
Thomas Hoffmann
Vice President
646-378-2931
thoffmann@troutgroup.com
www.troutgroup.com
 
 
Press spacebar to pause and continue. Press esc to stop.